Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder.
Prognosis
Tumor suppressor
UC
Urothelial carcinoma
ZSCAN4
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
25 Feb 2023
25 Feb 2023
Historique:
received:
09
12
2022
accepted:
14
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
With the advance in genome-wide analyses, genetic alternations have been found to play an important role in carcinogenesis and aggressiveness of UC. Through bioinformatic analysis of gene expression profiles of urinary bladder urothelial carcinoma (UBUC) from publicly available GEO dataset (GSE31684), Zinc finger and SCAN domain containing 4 (ZSCAN4) was identified as a significant downregulated gene in muscle-invasive bladder cancer when compared with non-muscle-invasive bladder cancer. The expression of ZSCAN4 was evaluated by immunohistochemistry in 340 upper urinary tract urothelial carcinomas (UTUCs) and 295 UBUCs. The expression profiles of ZSCAN4 and potential signaling pathways were analyzed bioinformatically. In UTUC, low expression of ZSCAN4 was significantly associated with advanced primary pT stage (P = 0.011), increased nodal metastasis (P = 0.002) and increased vascular invasion (P = 0.019). In UBUC, low expression of ZSCAN4 was significantly correlated with advanced primary pT stage (P < 0.001), increased nodal metastasis (P = 0.001), high histological grade (P = 0.003) and increased vascular invasion (P = 0.003). In survival analysis, low expression of ZSCAN4 acted as an independent negative prognostic factor for disease-specific survival and metastasis-free survival both in UTUC and UBUC. Gene ontology analysis showed that ZSCAN4 mRNA and its co-downregulated genes are associated with the mitotic cell cycle. Low expression of ZSCAN4 predicted worse outcome in urothelial carcinoma and might have potential regulatory role in cell mitosis.
Sections du résumé
BACKGROUND
BACKGROUND
With the advance in genome-wide analyses, genetic alternations have been found to play an important role in carcinogenesis and aggressiveness of UC. Through bioinformatic analysis of gene expression profiles of urinary bladder urothelial carcinoma (UBUC) from publicly available GEO dataset (GSE31684), Zinc finger and SCAN domain containing 4 (ZSCAN4) was identified as a significant downregulated gene in muscle-invasive bladder cancer when compared with non-muscle-invasive bladder cancer.
METHODS
METHODS
The expression of ZSCAN4 was evaluated by immunohistochemistry in 340 upper urinary tract urothelial carcinomas (UTUCs) and 295 UBUCs. The expression profiles of ZSCAN4 and potential signaling pathways were analyzed bioinformatically.
RESULTS
RESULTS
In UTUC, low expression of ZSCAN4 was significantly associated with advanced primary pT stage (P = 0.011), increased nodal metastasis (P = 0.002) and increased vascular invasion (P = 0.019). In UBUC, low expression of ZSCAN4 was significantly correlated with advanced primary pT stage (P < 0.001), increased nodal metastasis (P = 0.001), high histological grade (P = 0.003) and increased vascular invasion (P = 0.003). In survival analysis, low expression of ZSCAN4 acted as an independent negative prognostic factor for disease-specific survival and metastasis-free survival both in UTUC and UBUC. Gene ontology analysis showed that ZSCAN4 mRNA and its co-downregulated genes are associated with the mitotic cell cycle.
CONCLUSIONS
CONCLUSIONS
Low expression of ZSCAN4 predicted worse outcome in urothelial carcinoma and might have potential regulatory role in cell mitosis.
Identifiants
pubmed: 36841776
doi: 10.1186/s12957-023-02948-4
pii: 10.1186/s12957-023-02948-4
pmc: PMC9960215
doi:
Substances chimiques
ZSCAN4 protein, human
0
DNA-Binding Proteins
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Informations de copyright
© 2023. The Author(s).
Références
Hum Pathol. 2019 Feb;84:275-282
pubmed: 30359638
Cell. 2006 Jul 14;126(1):63-77
pubmed: 16839877
Annu Rev Pathol. 2009;4:251-85
pubmed: 18840072
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Nat Rev Cancer. 2005 Sep;5(9):713-25
pubmed: 16110317
Oncogene. 2003 May 15;22(19):2967-71
pubmed: 12771948
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6622-6
pubmed: 3413114
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Cell Res. 2013 Jan;23(1):92-106
pubmed: 23147797
Dev Biol. 2007 Jul 15;307(2):539-50
pubmed: 17553482
Annu Rev Biochem. 2016 Jun 2;85:659-83
pubmed: 27145846
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
pubmed: 24520177
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
Annu Rev Genomics Hum Genet. 2007;8:37-55
pubmed: 17887919
PLoS One. 2011 Apr 14;6(4):e18583
pubmed: 21533174
Stem Cell Rev Rep. 2022 Dec;18(8):2740-2756
pubmed: 35739386
Nucleus. 2011 Mar-Apr;2(2):119-35
pubmed: 21738835
J Clin Oncol. 2006 Dec 10;24(35):5552-64
pubmed: 17158541
Clin Cancer Res. 2012 Mar 1;18(5):1323-33
pubmed: 22228636
PLoS One. 2010 Nov 03;5(11):e13821
pubmed: 21072204
Genomics. 1999 Aug 1;59(3):335-8
pubmed: 10444335
Hum Mol Genet. 1995 Sep;4(9):1569-77
pubmed: 8541841
Oncotarget. 2017 Jul 18;8(29):47216-47229
pubmed: 28525382
Cancer Res. 2006 Aug 1;66(15):7401-4
pubmed: 16885334
Clin Cancer Res. 2012 Jun 15;18(12):3377-86
pubmed: 22553347
Curr Biol. 2010 Mar 23;20(6):521-6
pubmed: 20226664
Nat Rev Mol Cell Biol. 2017 Mar;18(3):187-201
pubmed: 28174430
Science. 1994 Jul 15;265(5170):415-7
pubmed: 8023167
Cancer Res. 2002 Dec 1;62(23):6973-80
pubmed: 12460915
Nat Rev Mol Cell Biol. 2009 Jan;10(1):9-20
pubmed: 19197328
Oncogene. 2020 Jun;39(26):4970-4982
pubmed: 32507861
Cancer Biol Ther. 2014 Aug;15(8):1094-105
pubmed: 24840609
Nat Commun. 2018 Apr 30;9(1):1723
pubmed: 29712904
Oncogene. 1998 Sep 3;17(9):1167-72
pubmed: 9764827
Nature. 2010 Apr 8;464(7290):858-63
pubmed: 20336070